Cancer Genetics — FY2017 Earnings Presentation
12 slides from Cancer Genetics's earnings presentation, Apr 2, 2018
Slide 1: Forward-Looking Statements
Forward-Looking Statements These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical develo
Slide 2: Everything we do is focused on 1 key idea
Everything we do is focused on 1 KEY idea .. deliver innovation & patient value by providing the most comprehensive capabilities For precision oncology development.
Slide 3: Revenue & Growth Highlights
Q4 Revenue Amounts in $ millions Revenue & Growth Highlights p.4 4-Year CAGR 17% $7.5M 4-Year CAGR 30% Full year Revenue Amounts in $ millions $29.0M $10.2M $18.0M $27.0M 2014 2015 2016 2017 $4.0M $5.5M $7.2M Q4 2014 Q4 2015 Q4 2016 Q4 2017
Slide 4: Revenues by Market & Customer Category
Revenues by Market & Customer Category Biopharma Services Supports 224 clinical trials and studies focused on Solid Tumor and Blood Cancers, including 59 for immuno-oncology indications. $14.6M Clinical Services 9.6% increase in test count year over year, to over 31 thousand tests performed driven b
Slide 5: 2017 Accomplishments
2017 Accomplishments p.6 Integration of vivoPharm Liquid Biopsy for Lung Cancer Launch AntigenID for Immuno-Oncology Launch Focus::Myeloma NGS Panel Validation [Mayo] NAPRT Methylation Assay Validation Validation of multiple Receptor Occupancy by Flow Cytometry Tests MDSC detection by Flow Cytometry
Slide 6: Full Year 2017 Financial Highlights
Full Year 2017 Financial Highlights FY 2017 revenues were $29.1 million, as compared to FY 2016 revenues of $27.0 million. Combined revenue from Biopharma Services and Discovery Services represented 63% of total revenue in 2017. Total operating expenses were increased approximately $3 million to $29
Slide 7: Q4 2017 Financial Highlights
Q4 2017 Financial Highlights Revenues of $7.5 million, 4% increase or $0.3 million over $7.2 million in Q4 2016. Biopharma Services revenue totaled $3.5 million compared to $4 million during Q4 2016. Clinical Services revenue totaled $1.9 million compared to $3 million during Q4 2016. Discovery Serv
Slide 8: Income Statement Items
Income Statement Items ($ in Thousands) Q4 2016 Q4 2017 FY 2016 FY 2017 Revenue $7,230 $7,523 $27,049 $29,121 Gross Profit $2,958 $2,284 $9,945 $11,051 Gross Margin (%) 41% 30% 37% 38% Research & Development (R&D) $1,161 $1,709 $5,967 $4,789 Sales & Marketing (S&M) $937 $1,553 $4,668 $4,990 General
Slide 9: Biotech and Pharma Highlights: Strong Year over Year & Quarterly Progress
Biotech and Pharma Highlights: Strong Year over Year & Quarterly Progress Biopharma bookings to billing ratio of 1.5 on $5.28M of Q4 2017 bookings Record quarterly biopharma bookings of $5.28M, up 11% year over year expected to drive future revenue 137% increase in biopharma projects from 125 to 297
Slide 10: Industry Leading Capabilities in Expanding Field of Immuno-Oncology
Confirm Expressed Somatic Mutations NGS: Whole Transcriptome Confirm by Sanger NGS: Exome / Oncology Panel Identify Somatic Mutations TMB & MSI HLA Type Epitope Prediction Immune Repertoire (PMBCs) Pathology Histology Neoantigen Validation KEY: DNA Analysis RNA Analysis Bioinformatic Analysis Indust
Slide 11: Headquarters and Office Locations
www.cgix.com www.cancergenetics.com CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 RUTHERFORD, NJ, USA #3-1-135/1A CNR Complex Mallapur Main Road, R.R. Dst. Hyderabad – 500 076, Telangana Phone: +91 040-2717-8178 HYDERABAD, INDIA Research Triangle Park 133 Southcente
Slide 12: concen CGIX — www.cor.com
concen CGIX — www.cor.com FE ees wren NASSAR ww.cancercenencs.com